## Approved Authorised Prescriber Applications Approved Date Product Profile

| Approved Date      | Product Profile                          |    |             |                    |
|--------------------|--|----|-------------|--------------------|
|                    | 3,4-Methylenedioxymethamphetamine (MDMA) |    | Psilocybine | <b>Grand Total</b> |
| 2023               |  | 3  | 2           | 5                  |
| Nov                |  | 1  | 1           | 2                  |
| Dec                |  | 2  | 1           | 3                  |
| 2024               |  | 9  | 11          | 20                 |
| Jan                |  | 1  | 2           | 3                  |
| Oct                |  | 1  | 4           | 5                  |
| Nov                |  | 3  | 5           | 8                  |
| Dec                |  | 4  |             | 4                  |
| 2025               |  | 6  | 4           | 10                 |
| Jan                |  | 1  |             | 1                  |
| Feb                |  | 2  | 1           | 3                  |
| Mar                |  |    | 1           | 1                  |
| Apr                |  | 3  | 2           | 5                  |
| <b>Grand Total</b> |  | 18 | 17          | 35                 |

**Note:** Blank cells or missing months indicate no approvals were made for the respective product during this time period

## **Sum of Number of New Patients**

AP Report 01/07/2024 - 31/12/2024

**Grand Total** 

| Reporting Period                  | Product Profile                          |    |             |                    |
|-----------------------------------|--|----|-------------|--------------------|
|                                   | 3,4-Methylenedioxymethamphetamine (MDMA) |    | Psilocybine | <b>Grand Total</b> |
| AP Report 01/07/2023 - 31/12/2023 |  | 1  | 0           | 1                  |
| AP Report 01/01/2024 - 30/06/2024 |  | 18 | 7           | 25                 |
| AP Report 01/07/2024 - 31/12/2024 |  | 34 | 23          | 57                 |
| Grand Total                       |  | 53 | 30          | 83                 |
| Sum of Total Number of Patients   |  |    |             |                    |
| Reporting Period                  | Product Profile                          |    |             |                    |
|                                   | 3,4-Methylenedioxymethamphetamine (MDMA) |    | Psilocybine | <b>Grand Total</b> |
| AP Report 01/07/2023 - 31/12/2023 |  | 1  | 0           | 1                  |
| AP Report 01/01/2024 - 30/06/2024 |  | 19 | 7           | 26                 |

**Note:** Authorised Prescribers (APs) must submit reports to the TGA every six months for each authorisation they hold and declare:

44

64

25

32

69

96

- the number of new patients commenced on treatment, and
- the number of total patients treated during the six month period (this may include patients who commenced treatment in a previous reporting period).

A prescriber of psychedelic medicines may hold an AP authorisation for either MDMA or psilocybine or separate authorisations for both medicines.

The information provided in six monthly reports is self-declared by applicants. No patient details are provided in the reports which means potential duplications cannot be removed. Therefore, the TGA cannot guarantee the data is an accurate representation of the number of patients accessing psychedelic medicinal products. Additionally, the TGA does not hold prescription data. A single patient may be prescribed additional doses of psychedelic medicines as clinically necessary.

Reporting periods are 1 January to 30 June and 1 July to 31 December and must be submitted within one month of the reporting period ending. The data provided reflects the information provided to the TGA at the time of the FOI request.

Document 1